Increasing evidence coming from both experimental and humans' studies strongly suggest the existence of a link between epilepsy, in particular temporal lobe epilepsy (TLE), and Alzheimer's disease (AD). Patients with mild cognitive impairment and AD are more prone to have seizures, and seizures seem to facilitate amyloid-β and tau deposits, thus promoting neurodegenerative processes. Consistent with this view, long-lasting drug-resistant TLE and AD have been shown to share several pathological and neuroimaging features. Even if studies addressing prevalence of interictal and subclinical epileptiform activity in these patients are not yet conclusive, their findings raise the possibility that epileptiform activity might negatively impact memory and hasten cognitive decline, either directly or by association with unrecognized silent seizures. In addition, data about detrimental effect of network hyperexcitability in temporal regions in the premorbid and early stages ofADopen up newtherapeutic opportunities for antiseizure medications and/or antiepileptic strategies that might complement or enhance existing therapies, and potentially modify disease progression. Here we provide a review of evidence linking epileptiform activity, network hyperexcitability, and AD, and their role promoting and accelerating neurodegenerative process. Finally, the effects of antiseizure medications on cognition and their optimal administration in patients with AD are summarized.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150253PMC
http://dx.doi.org/10.3233/ADR-200286DOI Listing

Publication Analysis

Top Keywords

epileptiform activity
12
temporal lobe
8
lobe epilepsy
8
alzheimer's disease
8
network hyperexcitability
8
antiseizure medications
8
epilepsy alzheimer's
4
disease preclinical
4
preclinical clinical
4
clinical evidence
4

Similar Publications

Hypotheses of pathophysiological mechanisms in epileptic encephalopathies: A review.

Brain Dev

January 2025

Department of Pediatric Neurology, Okayama University Hospital and Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

Introduction: Epileptic encephalopathy (EE) is a serious clinical issue that manifests as part of developmental and epileptic encephalopathy (DEE), particularly in childhood epilepsy. In EE, neurocognitive functions and behavior are impaired by intense epileptiform electroencephalogram (EEG) activity. Hypotheses of pathophysiological mechanisms behind EE are reviewed to contribute to an effective solution for EE.

View Article and Find Full Text PDF

Background: Altered network synchronization and rhythmic neural activity is observed in Alzheimer's disease (AD). Spontaneous epileptiform activity and/or seizures occur in an estimated 60% of AD cases, and having AD increases the likelihood of seizures when compared with people without dementia. Thus, network hyperexcitability can be an early feature and helpful for diagnosis and treatment.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

National Institute of Mental Health, Neurology and Neurosurgery, Budapest, Hungary.

Background: Growing evidence suggests that the imbalance between excitability and inhibitory neural activity is a key aspect of cognitive decline. Subclinical epileptiform activity (SEA) has been indicated as a marker of increased cortical excitability. While SEA is considered as a benign EEG sign in the elderly population, recent studies demonstrated its role in the progression of Alzheimer's disease.

View Article and Find Full Text PDF

Background: Sleep disturbances are common in Alzheimer's disease (AD) and occur at early stages. Hyperexcitability also arises during sleep and can lead to epileptiform activity and seizures that impact memory consolidation. The underlying mechanisms of sleep disturbances and hyperexcitability in AD pathology remain unclear but are likely associated with changes in brain networks and altered functional connectivity (FC).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Bioengineering, University of California, Los Angeles, CA, USA, Los Angeles, CA, USA.

Background: The initiation of amyloid plaque deposition signifies a crucial stage in Alzheimer's disease (AD) progression, which often coincides with the disruption of neural circuits and cognitive decline. While the role of excitatory-inhibitory balance is increasingly recognized in AD pathophysiology, targeted therapies to modulate this balance remain underexplored. This study investigates the effect of perampanel, a selective non-competitive AMPA receptor antagonist, in modulating neurophysiological changes in hAPP-J20 transgenic Alzheimer's mice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!